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The type of embolic protection does not influence
the outcome in carotid artery stenting
Vikram Iyer, MD,a Gianmarco de Donato, MD,b Koen Deloose, MD,a Patrick Peeters, MD,c
Fausto Castriota, MD,d Alberto Cremonesi, MD,d Carlo Setacci, MD,b and Marc Bosiers, MD,a
Dendermonde and Bonheiden, Belgium; and Siena and Cotignola, Italy
Objectives: The goal of this study was to review our experience with embolic protection devices (EPDs) during carotid
artery stenting (CAS). Specifically, we aimed to verify their clinical effectiveness and to compare clinical outcomes
between specific devices and types of EPDs.
Methods: The CAS databases at four participating centers were reviewed. Adverse events were defined as death, stroke
(>24 hours), or transient ischemic attack (TIA) (<24 hours). We compared the risk of procedural and 30-day events
between patients treated with and without an EPD. We also compared these risks between different EPDs and between
the different types of EPDs.
Results: A total of 3160 CAS procedures using nine EPDs were analyzed. The risk of a procedural adverse event was 0.9%
in protected and 2.3% in unprotected procedures (P .12). Compared with the most frequently used device (FilterWire,
Boston Scientific, Natick, Mass), there was no significant difference in the risk of procedural adverse events for any of the
other EPDs. There was, however, an increased risk of 30-day adverse events with the Accunet (Abbott Vascular,
Redwood, Calif) filter compared with the FilterWire (relative risk [RR] 2.67, confidence interval [CI] 1.41 to 5.04, P 
.005). Pairwise comparison of proximal occlusion balloons to filters, distal occlusion balloons to filters, and proximal to
distal occlusion balloons revealed no significant difference in the risk of procedural or 30-day adverse events. There was
no significant difference in risk of procedural events between eccentric and concentric filters, however, the relative risk of
eccentric compared with concentric filters at 30 days was 0.59 (unadjusted, CI 0.38 to 0.92, P .04). This difference was
still apparent after adjustment for risk factors (RR 0.61, CI 0.39 to 0.95, P  .06), but not after adjustment for risk
factors and stent-type [(open-cell vs closed-cell) RR 0.76, CI 0.47 to 1.22, P  .51].
Conclusion: The use of EPDs is associated with a low risk of procedural adverse events. We were unable to detect
significant differences in risks of procedural adverse events between different devices or types of devices. We speculate that
the observed differences seen at 30 days are largely attributable to differences in stent-type used. (J Vasc Surg 2007;46:
251-6.)Carotid artery stenting (CAS) and carotid endarterec-
tomy (CEA) have been the subjects of several randomized
controlled trials.1-5 Concern over cerebral embolization of
carotid plaque material during CAS led to the introduction
of embolic protection devices (EPDs).6 Although their use
during CAS has not been validated in randomized trials,
information from registries and observational studies sup-
port their routine use7,8 and most consider them to be the
standard of care. The three types of EPDs in current
practice are the filter (concentric or eccentric), distal bal-
loon occlusion, and proximal balloon occlusion with or
without flow reversal. Balloon occlusion, whether proximal
or distal, is associated with cerebral intolerance in 5% to
10% of cases.9,10 However, their main advantage is in
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doi:10.1016/j.jvs.2007.04.053avoidance of crossing the lesion unprotected (proximal
occlusion), or easier traversal of the lesion due to smaller
crossing profiles (distal occlusion). Occlusion balloons also
offer superior particle capture capability as demonstrated in
clinical and experimental studies.11 The main advantage of
filters is maintenance of flow to the brain throughout the
procedure, however, inability to cross very tight lesions and
distal ICA spasm are potential drawbacks.
Recently, we examined the effect of device characteris-
tics on the outcome following CAS with an emphasis on
stent design.12 The purpose of the present analysis is to
review our experience with embolic protection during
CAS. Specifically, we set out to verify the importance of
EPD use and to compare adverse neurological event rates
between specific devices and the different types of EPDs.
METHODS
The existing institutional databases of four participat-
ing centers were reviewed to select patients who underwent
CAS with commercially available EPDs and stents. Only
devices used in at least 25 procedures were included for
analysis. All patients were screened with preoperative du-
plex ultrasound and magnetic resonance angiography fol-
lowed by digital subtraction angiography at the time of the
procedure to confirm lesions appropriate for treatment
(symptomatic lesions 50%, asymptomatic lesions 80%,
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atic Carotid Endarterectomy Trial (NASCET) criteria).
CAS was performed with periprocedural antiplatelet ther-
apy and anticoagulation according to the existing institu-
tional standards of care as previously described.13,14 All
patients underwent neurological evaluation prior to the
procedure, 24 hours postprocedure, and at a 30-day fol-
low-up visit. All neurological investigations were per-
formed by a team of independent neurologists.
Information including age, gender, presence of symp-
toms, and medical risk factors were recorded. The presence
or absence of an EPD, the specific protection device used,
and the type of protection system used were recorded and
used for comparison. The specific stent used with each
protection device was also recorded.
An adverse event was defined as death, stroke (persist-
ing24 hours), or transient ischemic attack (TIA) (neuro-
logical deficit lasting 24 hours). Event rates were re-
corded as procedural (occurring during the procedure
only) or as 30-day (occurring during the procedure and up
to 30 days after).
Statistical analysis was conducted in the statistical soft-
ware package S-Plus 7.0, P-values below .05 (or 5%) are
termed statistically significant. The primary analysis com-
pared event rates between patients treated with and with-
out an EPD. It also compared adverse event rates between
the different protection devices used among patients
treated with an EPD. The secondary analysis compared
event rates between the types of protection systems (filter,
proximal occlusion, or distal occlusion) and the types of
filter-based protection systems (eccentric or concentric)
among the patients treated with them. Comparison of
event rates between different groups was based on (a two-
sided) Pearson’s 2 test with Yates correction whenever
appropriate (ie, whenever the expected cell counts ex-
ceeded five in at least 80% of all cells). Fisher exact test was
used in all other cases. Risk ratios (ie, relative risks) and
small-sample adjusted 95% confidence intervals were used
to quantify the comparison of complication event risks
between different groups. Due to the low number of
Table I. Patient demographics, risk factors, and lesion cha
CAS and for all subgroups
System Males
TOTAL N (%) 2116 (66.7)
Unprotected (n  30) 104
FilterWire (n  1640) 1055
Spider (n  191) 134
Emboshield (n  177) 119
Accunet (n  204) 154
Angioguard (n  518) 338
Trap (n  82) 56
Mo.Ma (n  150) 109
NPS (n  42) 28
Percusurge (n  26) 19
PVD, Peripheral vascular disease.events, no risk ratios were calculated for TIA, stroke, anddeath rates separately. Adjustment for risk factors was done
via exponential risk models, excluding risk factors one by
one if nonsignificant at the 5% significance level. P-values
for the secondary analysis were adjusted for multiple testing
errors through Bonferroni correction.
RESULTS
A total of 3281 CAS procedures were scheduled be-
tween 1997 and 2006. Of these, 11 were treated with CEA
instead due to unsuccessful common carotid engagement
or EPD delivery or deployment. Thirty-one of these were
treated with angioplasty alone, 37 were treated with either
a stent or EPD that was never commercially available, and
42 were treated using devices that were used in 25
procedures (range 1 to 13). This left 3160 CAS procedures
and nine EPDs available for analysis.
Patient and lesion characteristics are listed in Table I.
There was significant variability in the distribution of smok-
ing (P .01), presence of other peripheral vascular disease
(P  .005), hypercholesterolemia (P  .001), and lesion
calcification (P .005) between protection systems. Of the
3160 CAS procedures, 3030 (95.9%) were performed with
protection and 130 (4.1%) without. In all, there were 29
(0.9%) procedural and 90 (2.8%) 30-day events. There
were fewer procedural events when an EPD was used,
however this did not reach statistical significance (Table II).
Of the 3030 protected procedures, eccentric filters
(FilterWire, Boston Scientific Corp, Natick, Mass; Spider,
ev3, Plymouth, Minn) were used in 1831 (60.4%), concen-
tric filters (Emboshield, Abbott Vascular, Redwood City,
Calif; Angioguard, Cordis, Miami Lakes, Fla; Trap, ev3,
Plymouth, Minn; Accunet, Abbott Vascular, Redwood
City, Calif) in 981 (32.4%), proximal occlusion (NPS,
W. L. Gore & Associates, Flagstaff, Ariz; Mo.Ma, Invatec,
Roncadelle, Italy) in 192 (6.3%) and distal occlusion (Per-
cusurge, Medtronic, Santa Rosa, Calif) in 26 (0.9%) cases.
Closed cell stents in which all stent-struts are intercon-
nected (Carotid Wallstent, Boston Scientific Corp, Natick,
Mass; X-act, Abbott Vascular, Redwood City, Calif; Nex-
tent, Endotex, Cupertino, Calif) were used in 2120
ristics for total population of 3160 patients undergoing
e  80 Symptoms Smoke
(16.1) 1309 (41.4) 1195 (37.8)
7 65 55
290 676 567
28 56 76
23 73 76
41 84 93
81 234 206
13 43 31
17 49 53
6 15 23
3 14 15racte
Ag
509(70.0%) cases and open cell stents in which not all stent-
l; TIA
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Fla; Exponent, Medtronic, Santa Rosa, Calif; Protégé, ev3,
Plymouth, Minn; Acculink, Abbott Vascular, Redwood
City, Calif) were used in 910 (30%) cases. Table III de-
scribes the proportion of closed cell stents used in conjunc-
tion with each protection type.
The procedural and 30-day events are expressed in
absolute risks and risks relative to the most commonly used
EPD in this study (FilterWire, Boston Scientific) in Tables
IV and V. This comparison is not adjusted for risk factors
due to low sample size for some of the devices. When
comparing individual EPDs to the FilterWire, a statistically
significant increased 30-day event rate was found for the
Accunet (Abbott Vascular) concentric filter. There was also
an increased 30-day and procedural event rate observed for
Table I. Continued.
Hypertension Diabetes Other PVD Hy
2278 (72.1) 823 (26.0) 1432 (45.3)
100 23 68
1179 450 709
133 52 102
131 48 87
156 54 115
374 119 224
57 26 36
106 38 75
24 6 3
18 7 13
Table II. Procedural and 30-day adverse events comparin
Event-time Frequency - N (%
30-days
Protected (n  3030) 87 (2.9) [68 TIA; 13 strok
Unprotected (n  130) 3 (2.3) [3 TIA]
Procedural
Protected (n  3030) 26 (0.9) [20 TIA; 6 stroke
Unprotected (n  130) 3 (2.3) [3 TIA]
RR, Relative risk compared with protected stenting; CI, confidence interva
Table III. Proportion of closed-cell stents used in
conjunction with the different types of protection
Protection-type Closed-cell stents used - N (%)
Unprotected (n  130) 114 (87.7)
Concentric filter* (n  981) 488 (49.7)
Eccentric filter† (n  1831) 1467 (80.1)
Proximal occlusion‡ (n  192) 141 (73.4)
Distal occlusion§ (n  26) 24 (92.3)
*Emboshield, Angioguard, Trap, Accunet.
†FilterWire, Spider.
‡NPS, Mo.Ma.
§Percusurge.the Percusurge (Medtronic) distal occlusion balloon, al-though not statistically significant. Two patients in this
group had events. One of them was a procedural event at
which time visible leaking of the balloon was noted. The
other was a late event of unknown cause.
Risk ratios of procedural and 30-day events comparing
the different types of protection systems before and after
adjustment for risk factors are listed in Table VI. A statisti-
cally significant difference was found in favor of eccentric
filters compared with concentric filters at 30 days only (P
.04). After adjustment for risk factors, a trend remained in
favor of eccentric filters (P  .06). After adjustment for
stent-type (closed cell vs open cell) after-which this differ-
ence was no longer apparent (P  .51).
DISCUSSION
In the present retrospective analysis, we were unable to
show a statistically significant clinical benefit for the use of
EPDs despite 60% fewer procedural events in protected
procedures. This may be due to small sample size in the
unprotected group and low event rates in either group.
Interestingly, each of the three 30-day events in the unpro-
tected group represented events that occurred during the
procedure itself. There also exists potential selection bias, as
the procedures performed without neuroprotection were
done before EPDs were widely available and so lesions with
higher risk for embolization may have been deferred to
CEA or medical management.
Diffusion-weighted imaging has recently been used to
demonstrate a reduction in embolic events with the use of
olesterolemia Calcification Restenosis after surgery
0 (63.0) 777 (24.5) 204 (6.5)
93 3 3
999 540 127
114 41 9
121 10 9
148 54 10
328 101 32
57 4 9
95 14 4
16 9 0
19 1 1
ients treated with and without a protection system
RR 95% CI P
death]
1.25 0.40-3.88 1.00
0.38 0.12-1.24 .12
, transient ischemic attack.perch
199g pat
)
e; 7
]EPDs during CAS.15 Although there was no significant
nce in
nce in
CI, c
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control groups in this study, the authors noted a correlation
between the number of new cerebral lesions and stroke.
Conversely, another prospective study comparing filter-
protected with unprotected patients, saw significantly more
micro-emboli on transcranial Doppler ultrasound in the
filter group.16 Again, there was no statistical difference in
Table IV. Procedural adverse events for nine EPD system
System Frequency - N (%)
FilterWire (n  1640) 16 (1.0) [11 TIA; 5 stroke]
Spider (n  191) 0 (0)
Emboshield (n  177) 0 (0)
Accunet (n  204) 1 (0.49) [1 TIA]
Angioguard (n  518) 5 (0.97) [5 TIA]
Trap (n  82) 1 (1.22) [1 TIA]
Mo.Ma (n  150) 1 (0.67) [1 TIA]
NPS (n  42) 1 (2.38) [1 stroke]
Percusurge (n  26) 1 (3.85) [1 TIA]
RR, Relative risk compared with FilterWire (Boston Scientific); CI, confide
Table V. Thirty-day adverse events for nine EPD systems
System Frequency - N (%)
FilterWire (n  1640) 36 (2.2) [23 TIA; 9 stroke; 4
Spider (n  191) 4 (2.1) [4 TIA]
Emboshield (n  177) 6 (3.39) [5 TIA; 1 death]
Accunet (n  204) 12 (5.88) [11 TIA; 1 stroke]
Angioguard (n  518) 17 (3.28) [14TIA; 2 stroke;
Trap (n  82) 2 (2.44) [2 TIA]
Mo.Ma (n  150) 6 (4.0) [6 TIA]
NPS (n  42) 2 (4.76) [1 stroke; 1 death
Percusurge (n  26) 2 (7.69) [2 TIA]
RR, Relative risk compared with FilterWire (Boston Scientific); CI, confide
Table VI. Comparison between different types of protect
and stent-type
Procedural ev
Comparison RR 95% CI
Proximal occlusion vs filter
Unadjusted 1.28 0.30-5.37
Adjusted for RF 1.34 0.22-4.54
Adjusted for RF, ST 1.34 0.22-4.54
Distal occlusion vs filter
Unadjusted 4.56 0.64-32.52
Adjusted for RF 4.34 0.24-20.60
Adjusted for RF, ST 4.32 0.24-20.90
Distal vs proximal occlusion
Unadjusted 3.57 0.34-38.05
Adjusted for RF 3.57 0.34-38.05
Adjusted for RF, ST 3.57 0.34-38.05
Eccentric vs concentric filter
Unadjusted 1.25 0.52-3.03
Adjusted for RF 1.31 0.56-3.41
Adjusted for RF, ST 1.33 0.55-3.57
RF, Risk factors; ST, Stent-type (open-cell or closed-cell); RR, relative risk;clinical outcome between groups. In the latter study, selec-tion bias could have played a role, favoring higher-risk
lesions in the filter group. Both these studies, like the
present one, suffered from small sample sizes relative to
event rates. In order to resolve this issue, two large reviews
pooled data from multiple reports and registries and
showed significantly fewer neurological events after the
introduction of EPDs.8,17 Still, while EPDs may be bene-
RR 95% CI P
0.00 0.00- .40
0.00 0.00- .40
0.50 0.07-3.75 1.00
0.99 0.36-2.68 1.00
1.24 0.17-9.20 .57
0.68 0.09-5.09 1.00
2.39 0.32-17.57 .35
3.80 0.52-27.59 .24
terval; TIA, transient ischemic attack.
RR 95% CI P
th]
0.95 0.34-2.64 1.00
1.54 0.66-3.60 .29
2.67 1.41-5.04 .005
th] 1.49 0.85-2.64 .19
1.10 0.27-4.48 .70
1.81 0.78-4.23 .16
2.12 0.53-8.52 .24
3.38 0.86-13.29 .12
terval; TIA, transient ischemic attack.
ystems, before and after adjustment for risk factors
30-day events
P RR 95% CI P
1.00 1.52 0.75-3.13 1.00
1.00 1.57 0.70-3.06 1.00
1.00 1.59 0.71-3.10 1.00
1.00 2.72 0.71-10.51 .96
1.00 2.69 0.44-8.53 1.00
1.00 3.38 0.55-10.87 .54
1.00 1.79 0.40-7.96 1.00
1.00 1.79 0.40-7.96 1.00
1.00 1.79 0.40-7.96 1.00
1.00 0.59 0.38-0.92 0.04
1.00 0.61 0.39-0.95 0.06
1.00 0.76 0.47-1.22 0.51
onfidence interval.sdea
1 dea
]ion s
entsficial, concurrent advancements in stent and guidewire
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potentially played a role. Even so, sufficient data is available
to state that EPDs are safe and feasible, and so continued
use is likely justified until further information from ran-
domized trials is available to clarify their role.
One of the main difficulties in determining equivalence
or superiority of any particular EPD is caused by the pres-
ence of confounders. In the present study, we adjusted for
patient risk factors when evaluating the different types of
EPDs. We were unable to do the same when analyzing the
specific devices due to lower sample sizes. It is unlikely,
however, that this would have had a great impact, given
that risk factor adjustment did not have a major effect on
our secondary analysis. A more significant confounder re-
sults from the frequent device pairing that occurs (ie, a
given EPD is usually sold with a corresponding stent from
the same manufacturer) due to product marketing. With
recent evidence suggesting an impact of stent-design on
CAS outcomes18 this becomes even more important.
For example, significantly more adverse events were
seen at 30 days, but not at the time of the procedure, for the
Accunet (Abbott Vascular) filter compared with the Filter-
Wire (Boston Scientific). Open cell stents were used with
this device in over 65% of cases, the predominant one being
Acculink (Abbott Vascular) stent which has the highest free
cell area of the stents used in this study. In the light of our
previous report,18 it is due to the larger free cell area, which
leads to a greater risk of plaque debris embolization
through the struts of the stent. This showed to significantly
increase the risk on 30-day adverse events, and it is there-
fore that we believe this difference seen at 30 days was
primarily the effect of the selection of the stent-type with
the large free cell area.
We did not initially adjust for stent-type in comparing
the specific EPDs, because in most cases it is not practical to
“unpair” the devices, and so the information provided
would not be clinically relevant for most operators. How-
ever, observed differences at 30 days but not at the time of
the procedure needs explanation. It is possible that vessel wall
injury caused by the EPD can result in late events. An animal
model demonstrated a correlation between debris capture and
vessel wall injury from filter placement19 during the proce-
dure. It is possible that this can translate to late embolic events
from wall debris or thrombus. Alternatively, we thought it
more likely that the 30-day differences we observed between
eccentric and concentric filters and probably also for the
Accunet (Abbott Vascular) filter were the result of the differ-
ent stent-designs used. To confirm this, we performed an
analysis on the comparison between EPD types adjusting for
stent type (open cell vs closed cell). Following adjustment, the
advantage of eccentric over concentric filters at 30 days disap-
peared. Some of this was the result of adjusting for risk factors,
however, the trend that still existed disappeared after adjust-
ment for stent-type. It appears that the observed benefit was
largely due to the use of closed cell stents.
In the present analysis both filter types performed well
at the time of the procedure. In comparison, the procedural
event rate observed with the only distal occlusion deviceused in this study was quite high (3.70%), although not
statistically significant. Device malfunction was possibly the
cause of one of these events (balloon leakage). The NPS
(Gore) device also performed less well than the other
devices (2.38% procedural event rate). It is possible, given
the lower sample sizes for these devices in our study that a
certain learning curve exists, as noted by others.20,21
In their recent publication, Zahn et al found that
in-hospital combined event rates were comparable whether
filters or distal occlusive devices were used during CAS.22
This was despite there being double the proportion of
lesions requiring predilatation in the distal occlusion group.
This emphasizes the potential advantage of these devices
given their slimmer crossing-profile. This may be more
relevant than the higher capture counts seen with occlusion
devices11 as many small particulate debris appear to be
clinically silent.15 Another review had similar findings,
however, they noted a 10% rate of cerebral intolerance to
balloon occlusion.10 In order to avoid this, they stated a
preference for filter devices except in cases of severe critical
stenoses. Such a lesion-specific approach to device selection
seems appropriate unless a clear advantage of one device
over the other is established.
Although the results of this subanalysis fail to prove
earlier published potential theoretical advantages and dis-
advantages of different EPD in specific indications.23 It is
claimed that different geometries and working principles of
EPDs on the market provide each with unique functional
properties and that the individual characteristics of each
devicemaymake it an attractive choice in one circumstance,
but render it less desirable in other situations. In-depth
investigation is required to confirm this thesis.
The present study is limited due to its retrospective
nature. Potential selection biases may have occurred in
selecting the unprotected CAS patients as discussed
above. It is also possible that selection bias can occur
when choosing a particular EPD. Although tailoring the
choice of device to the lesion is likely appropriate, this
was not done in the present study. This stems from the
fact that the procedures were almost all performed in the
context of a CAS training program or trial sponsored by
a particular company. Therefore, the date of the inter-
vention was the predominant factor in determining
which device was used. Device-specific complications
such as arterial damage, spasm, and cerebral intolerance
were not recorded in this review. It would have been
interesting to note if these events impacted clinical out-
come, although we suspect not given the observations of
others.20 Similarly, patients did not undergo routine CT
or MRI examinations or transcranial Doppler monitor-
ing during the procedure, so an objective measure of the
degree of embolization occurring with correlation to
clinical outcome could not be made. Due to the low
number of events, it was only possible to investigate risk
ratios for the total procedural and 30-day adverse event
rates between the different modalities.
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The use of EPDs is associated with a low procedural
complication rate. There was no significant difference in
procedural adverse neurological events observed for any of
the EPDs or types of EPDs. The differences seen in 30-day
events observed are largely attributable to the difference in
stent-type (closed vs open cell) used in conjunction with
the EPD.
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